24 year outcomes of hepatitis B vaccination in Hangzhou, China

Hum Vaccin Immunother. 2015;11(8):2051-60. doi: 10.1080/21645515.2015.1008873.

Abstract

To evaluate the impact of the universal infant HepB vaccination program on hepatitis B virus infection in Hangzhou, China. Hepatitis B incidences and HepB vaccination rates of Hangzhou from 1990 to 2003 were acquired from the historical paper-documents, while which were derived from China Information System for Diseases Control and Prevention and Zhejiang Information System for Immunization Program respectively from 2004 to 2013. A serology survey among person aged 0-59 y was conducted in Hangzhou in 2006. Participants were selected by stratified, multi-stage random sampling. Serum specimens were tested for HBsAg, anti-HBs , anti-HBc , HBeAg and anti-HBe by ELISA. For the past 24 years, hepatitis B incidence and mortality of Hangzhou declined dramatically (χ(2) = 3.2 × 10(4); χ(2) = 172.443; both P for trend < 0.001). Both urban and rural incidence descended (χ(2)urban = 1.904 × 10(4); χ(2)rural = 1.633 × 10(4) ; both P for trend < 0.001).Hepatitis B patients mainly concentrated in 20-40 y old; workers and farmers were the main infection occupations, which was varies in different years (χ(2) = 1.619 × 10(3), P < 0.001). Significant association was found between incidence of hepatitis B and HepB vaccination rate (r = 0 .946, χ(2) = 11.813, Pfor trend = 0.001). A total of 5605 participants aged 0-59 y included in this serological survey. The prevalence of HBsAg, anti-HBs, anti-HBc, HBeAg and anti-HBe were 6.19%, 45.83%, 57.25%, 0.62%, and 4.37%, respectively. Hangzhou has successfully integrated the HepB into routine immunization programs and this has had a significant impact on decreasing the incidence of hepatitis B infection.

Keywords: descriptive epidemiology; hepatitis B; incidence; outcomes; vaccination.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • China / epidemiology
  • Enzyme-Linked Immunosorbent Assay
  • Hepatitis B / epidemiology*
  • Hepatitis B / mortality
  • Hepatitis B / prevention & control*
  • Hepatitis B Antibodies / blood*
  • Hepatitis B Antigens / blood*
  • Hepatitis B Vaccines / administration & dosage*
  • Hepatitis B Vaccines / immunology*
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Middle Aged
  • Seroepidemiologic Studies
  • Survival Analysis
  • Treatment Outcome
  • Young Adult

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Antigens
  • Hepatitis B Vaccines